The formal integration of the IDH status into the WHO glioma classification solidifies IDH mutations as essential diagnostic and prognostic molecular markers,17,29,34 emphasizing the need for molecularly driven therapeutic approaches to improve GBM patient outcomes. The gene discussed is IDH2; the disease is glioma.